Page last updated: 2024-12-08
n-methylcorydaldine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-methylcorydaldine: isolated from Annona squamosa twigs; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Annona | genus | A plant genus of the family ANNONACEAE. It has edible fruit and seeds which contain acetogenins and benzoquinazoline and other alkaloids.[MeSH] | Annonaceae | The custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH] |
| Annona squamosa | species | [no description available] | Annonaceae | The custard-apple plant family of the order Magnoliales, subclass Magnoliidae, class Magnoliopsida. Some members provide large pulpy fruits and commercial timber. Leaves and wood are often fragrant. Leaves are simple, with smooth margins, and alternately arranged in two rows along the stems.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 303906 |
| CHEMBL ID | 504722 |
| CHEBI ID | 67411 |
| SCHEMBL ID | 11923834 |
| MeSH ID | M0560351 |
Synonyms (33)
| Synonym |
|---|
| AKOS005421370 |
| 6514-05-2 |
| nsc194246 |
| nsc-194246 |
| 1(2h)-isoquinolinone,4-dihydro-6,7-dimethoxy-2-methyl- |
| MLS001049023 |
| smr000387036 |
| NCGC00017387-01 |
| tnp00337 |
| NCGC00142564-01 |
| STK236401 |
| 6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolin-1(2h)-one |
| 6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolin-1-one |
| CHEMBL504722 , |
| n-methylcorydaldine |
| chebi:67411 , |
| NCGC00017387-02 |
| 6,7-dimethoxy-2-methyl-3,4-dihydro-1(2h)-isoquinolinone |
| SCHEMBL11923834 |
| bdbm50349827 |
| HMS2268G03 |
| 6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-one |
| isocarbostyril, 3,4-dihydro-6,7-dimethoxy-2-methyl- |
| n-methyl-6,7-dimethoxytetrahydroisoquinol-1-one |
| 6,7-dimethoxy-2-methyl-3,4-dihydro-1(2h)-isoquinolinone # |
| 1(2h)-isoquinolinone, 3,4-dihydro-6,7-dimethoxy-2-methyl- |
| BDIZBBGNYDRCCA-UHFFFAOYSA-N |
| 2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-1-one |
| DTXSID80307685 |
| 6,7-dimethoxy-2-methyl-3,4-dihydro-2h-isoquinolin-1-one |
| Q27135873 |
| HY-N10763 |
| CS-0635995 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| quinolone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 0.0291 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 (µMol) | 1,000.0000 | 0.0340 | 3.9871 | 10.0000 | AID610480 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (17)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID361149 | Inhibition of 12-O-tetradecanoylphorbol 13-acetate-induced transformation of mouse JB6 cells after 14 days by soft agar assay | 2002 | Journal of natural products, Jul, Volume: 65, Issue:7 | Constituents of the twigs of Hernandia ovigera that inhibit the transformation of JB6 murine epidermal cells. |
| AID610481 | Antimelanogenic activity in alpha-MSH-stimulated mouse B16F10 cells pretreated for 30 mins before alpha-MSH challenge measured after 48 hrs by ELISA reader | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Gusanlungionosides A-D, potential tyrosinase inhibitors from Arcangelisia gusanlung. |
| AID610480 | Inhibition of mushroom tyrosinase using L-DOPA after 10 mins by ELISA reader | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Gusanlungionosides A-D, potential tyrosinase inhibitors from Arcangelisia gusanlung. |
| AID610482 | Cytotoxicity against mouse B16F10 cells up to 200 ug/mL | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Gusanlungionosides A-D, potential tyrosinase inhibitors from Arcangelisia gusanlung. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||